Astellas Pharma

Live  

Astellas Pharma is a Japanese pharmaceutical company that was created in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. The company focuses on the research, development, and commercialization of pharmaceutical products in a variety of therapeutic areas, including immunology, oncology, and urology.
One of Astellas Pharma's primary areas of focus is in the development of treatments for oncology-related diseases. They have a strong portfolio of oncology products, including treatments for prostate, bladder, and pancreatic cancer. In addition, the company is also committed to developing treatments for rare diseases, such as Duchenne muscular dystrophy and acute myeloid leukemia.
Astellas Pharma also has a global presence, with operations in Asia, Europe, North America, and Latin America. They operate research and development centers in Japan, the United States, and the Netherlands, as well as manufacturing facilities in various countries.
Overall, Astellas Pharma is dedicated to improving the health and well-being of patients worldwide through the development of innovative and effective pharmaceutical products.

Astellas Pharma is a company that makes medicine to help people feel better when they are sick. Think of it like a team of scientists and doctors working together to find new ways to help people fight illnesses, like infections or diseases that make them very tired or weak.
To make money, Astellas sells the medicines they create to hospitals, doctors, and pharmacies. When a new medicine is approved for use, it can be expensive, and many people need it, so the company earns money from those sales. They also sometimes partner with other companies or research organizations to create even better medicines.
Astellas is successful for a few important reasons. First, they do a lot of research to find new ideas and treatments, which helps them create effective medicines that many people need. Second, they follow strict rules and regulations to make sure their medicines are safe. This builds trust with doctors and patients. Lastly, they keep looking for new problems to solve in health care, like by researching rare diseases or new treatments for cancer.
In the future, Astellas is likely to stay successful because they are always innovating and adapting. As people get older or as new health problems come up, there will always be a need for better treatments. Plus, medicine is always getting more advanced, which means there will be new discoveries and opportunities for companies like Astellas to create helpful medicines that can improve lives.

VGhlcmUgYX JlIGEgZmV3 IHRoaW5ncy B0aGF0IGFy ZSBzcGVjaW FsIGFib3V0 IEFzdGVsbG FzIFBoYXJt YSBhcyBhIG NvbXBhbnk6 PGJyPjEuIF N0cmVuZ3Ro IGluIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudDog QXN0ZWxsYX MgUGhhcm1h IGhhcyBhIH N0cm9uZyBm b2N1cyBvbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQsIHdpdG ggYSBzaWdu aWZpY2FudC Bwb3J0aW9u IG9mIGl0cy ByZXZlbnVl cyBiZWluZy BpbnZlc3Rl ZCBpbiB0aG lzIGFyZWEu IFRoaXMgaG FzIGFsbG93 ZWQgdGhlbS B0byBkZXZl bG9wIGlubm 92YXRpdmUg bWVkaWNpbm VzIGFuZCB0 cmVhdG1lbn RzIGZvciBh IHdpZGUgcm FuZ2Ugb2Yg aWxsbmVzc2 VzIGFuZCBj b25kaXRpb2 5zLjxicj4y LiBHbG9iYW wgcHJlc2Vu Y2U6IEFzdG VsbGFzIFBo YXJtYSBpcy BhIHRydWx5 IGdsb2JhbC Bjb21wYW55 LCB3aXRoIG xvY2F0aW9u cyBhbmQgb3 BlcmF0aW9u cyBpbiBvdm VyIDUwIGNv dW50cmllcy B3b3JsZHdp ZGUuIFRoaX MgaGFzIGVu YWJsZWQgdG hlbSB0byBy ZWFjaCBhIG Jyb2FkIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyBhbmQgc2 VydmljZXMg dG8gYSBkaX ZlcnNlIHJh bmdlIG9mIH BhdGllbnQg cG9wdWxhdG lvbnMuPGJy PjMuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog QXN0ZWxsYX MgUGhhcm1h IHByaW9yaX RpemVzIHRo ZSBuZWVkcy BhbmQgd2Vs bC1iZWluZy BvZiBwYXRp ZW50cyBhYm 92ZSBhbGwg ZWxzZS4gVG hleSBzdHJp dmUgdG8gdW 5kZXJzdGFu ZCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIHdv cmsgdG8gZG V2ZWxvcCB0 cmVhdG1lbn RzIHRoYXQg YWRkcmVzcy B0aGVpciBz cGVjaWZpYy Bjb25kaXRp b25zLjxicj 40LiBDb21t aXRtZW50IH RvIHN1c3Rh aW5hYmlsaX R5OiBUaGUg Y29tcGFueS BoYXMgYSBz dHJvbmcgY2 9tbWl0bWVu dCB0byBzdX N0YWluYWJp bGl0eSwgaW 1wbGVtZW50 aW5nIGVjby 1mcmllbmRs eSBwcmFjdG ljZXMgYW5k IGluaXRpYX RpdmVzIGlu IGl0cyBvcG VyYXRpb25z IGFuZCBwcm 9kdWN0aW9u IHByb2Nlc3 Nlcy4gVGhl eSBhbHNvIH dvcmsgdG8g ZW5zdXJlIG V0aGljYWwg YW5kIHJlc3 BvbnNpYmxl IGJ1c2luZX NzIHByYWN0 aWNlcy48Yn I+NS4gQ29s bGFib3JhdG l2ZSBwYXJ0 bmVyc2hpcH M6IEFzdGVs bGFzIFBoYX JtYSBiZWxp ZXZlcyBpbi Bjb2xsYWJv cmF0aW9uIG FuZCB3b3Jr aW5nIHdpdG ggb3RoZXIg Y29tcGFuaW VzLCBvcmdh bml6YXRpb2 5zLCBhbmQg aW5kaXZpZH VhbHMgdG8g YWNoaWV2ZS B0aGVpciBt aXNzaW9uIG 9mIGltcHJv dmluZyB0aG UgbGl2ZXMg b2YgcGF0aW VudHMuIFRo ZXkgaGF2ZS Bmb3JtZWQg cGFydG5lcn NoaXBzIHdp dGggdmFyaW 91cyBhY2Fk ZW1pYyBpbn N0aXR1dGlv bnMsIHJlc2 VhcmNoIG9y Z2FuaXphdG lvbnMsIGFu ZCBvdGhlci BwaGFybWEg Y29tcGFuaW VzIHRvIGFk dmFuY2UgaG VhbHRoY2Fy ZSBpbm5vdm F0aW9uLjxi cj42LiBDb3 Jwb3JhdGUg c29jaWFsIH Jlc3BvbnNp YmlsaXR5Oi BBc3RlbGxh cyBQaGFybW EgaXMgY29t bWl0dGVkIH RvIGdpdmlu ZyBiYWNrIH RvIHRoZSBj b21tdW5pdH kgYW5kIGlt cHJvdmluZy BwZW9wbGUn cyBsaXZlcy B0aHJvdWdo IGl0cyBjb3 Jwb3JhdGUg c29jaWFsIH Jlc3BvbnNp YmlsaXR5IG luaXRpYXRp dmVzLiBUaG lzIGluY2x1 ZGVzIGludm VzdGluZyBp biBlZHVjYX Rpb24sIHBy b21vdGluZy BlbXBsb3ll ZSBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiwgYW5k IHN1cHBvcn RpbmcgbG9j YWwgY29tbX VuaXRpZXMu

QXN0ZWxsYX MgUGhhcm1h IGlzIGEgZ2 xvYmFsIHBo YXJtYWNldX RpY2FsIGNv bXBhbnkgdG hhdCBmb2N1 c2VzIG9uIG RldmVsb3Bp bmcsIG1hbn VmYWN0dXJp bmcsIGFuZC BtYXJrZXRp bmcgaW5ub3 ZhdGl2ZSBh bmQgaGlnaC 1xdWFsaXR5 IG1lZGljaW 5lcyBmb3Ig dGhlIHRyZW F0bWVudCBv ZiB2YXJpb3 VzIGRpc2Vh c2VzIGFuZC Bjb25kaXRp b25zLiBJdH MgYnVzaW5l c3MgbW9kZW wgcmV2b2x2 ZXMgYXJvdW 5kIHRoZSBm b2xsb3dpbm cga2V5IGFz cGVjdHM6PG JyPjEuIFJl c2VhcmNoIG FuZCBEZXZl bG9wbWVudC AoUiZEKTog QXN0ZWxsYX MgUGhhcm1h IGludmVzdH MgaGVhdmls eSBpbiBSJk QgdG8gZGlz Y292ZXIgYW 5kIGRldmVs b3AgbmV3IG RydWdzIGFu ZCB0cmVhdG 1lbnRzLiBU aGUgY29tcG FueSBoYXMg YSBnbG9iYW wgbmV0d29y ayBvZiByZX NlYXJjaCBj ZW50ZXJzIG FuZCBlbXBs b3lzIGEgdG VhbSBvZiBz Y2llbnRpc3 RzIGFuZCBy ZXNlYXJjaG VycyB3aG8g d29yayBjb2 xsYWJvcmF0 aXZlbHkgdG 8gaWRlbnRp ZnkgYW5kIG RldmVsb3Ag cG90ZW50aW FsIGRydWcg Y2FuZGlkYX Rlcy48YnI+ Mi4gU3RyYX RlZ2ljIFBh cnRuZXJzaG lwcyBhbmQg Q29sbGFib3 JhdGlvbnM6 IEFzdGVsbG FzIFBoYXJt YSBjb2xsYW JvcmF0ZXMg d2l0aCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIG FjYWRlbWlj IGluc3RpdH V0aW9ucywg YW5kIHJlc2 VhcmNoIG9y Z2FuaXphdG lvbnMgdG8g YWNjZXNzIG 5ldyB0ZWNo bm9sb2dpZX MsIHNoYXJl IGtub3dsZW RnZSwgYW5k IGFkdmFuY2 UgaXRzIFIm RCBlZmZvcn RzLiBUaGUg Y29tcGFueS BhbHNvIHNl ZWtzIHRvIG FjcXVpcmUg b3IgbGljZW 5zZSBwcm9t aXNpbmcgY2 9tcG91bmRz IGFuZCB0ZW Nobm9sb2dp ZXMgZnJvbS BleHRlcm5h bCBzb3VyY2 VzIHRvIGV4 cGFuZCBpdH MgcHJvZHVj dCBwaXBlbG luZS48YnI+ My4gTWFudW ZhY3R1cmlu ZyBhbmQgU3 VwcGx5IENo YWluOiBBc3 RlbGxhcyBQ aGFybWEgaG FzIGEgZ2xv YmFsIG1hbn VmYWN0dXJp bmcgYW5kIH N1cHBseSBu ZXR3b3JrIH RoYXQgcHJv ZHVjZXMgYW 5kIGRpc3Ry aWJ1dGVzIG l0cyBwcm9k dWN0cyB0by B2YXJpb3Vz IG1hcmtldH Mgd29ybGR3 aWRlLiBUaG UgY29tcGFu eSBlbnN1cm VzIHRoZSBo aWdoZXN0IH N0YW5kYXJk cyBvZiBxdW FsaXR5IGFu ZCBjb21wbG lhbmNlIGlu IGl0cyBtYW 51ZmFjdHVy aW5nIHByb2 Nlc3NlcyB0 byBtZWV0IH JlZ3VsYXRv cnkgcmVxdW lyZW1lbnRz Ljxicj40Li BNYXJrZXRp bmcgYW5kIF NhbGVzOiBB c3RlbGxhcy BQaGFybWEg bWFya2V0cy BpdHMgcHJv ZHVjdHMgdG hyb3VnaCBh IG5ldHdvcm sgb2Ygc2Fs ZXMgcmVwcm VzZW50YXRp dmVzIHRvIG hlYWx0aGNh cmUgcHJvZm Vzc2lvbmFs cyBhbmQgaG 9zcGl0YWxz LiBUaGUgY2 9tcGFueSB1 c2VzIHZhcm lvdXMgbWFy a2V0aW5nIH N0cmF0ZWdp ZXMgdG8gcm Fpc2UgYXdh cmVuZXNzIG FuZCBwcm9t b3RlIGl0cy Bwcm9kdWN0 cywgaW5jbH VkaW5nIHRy YWRpdGlvbm FsIGFkdmVy dGlzaW5nLC BtZWRpY2Fs IGNvbmZlcm VuY2VzLCBh bmQgZWR1Y2 F0aW9uYWwg cHJvZ3JhbX MuPGJyPjUu IEdsb2JhbC BHcm93dGgg YW5kIEV4cG Fuc2lvbjog QXN0ZWxsYX MgUGhhcm1h IGhhcyBhIG ZvY3VzZWQg YXBwcm9hY2 ggdG8gZXhw YW5kIGl0cy BnbG9iYWwg Zm9vdHByaW 50IGJ5IGVu dGVyaW5nIG 5ldyBtYXJr ZXRzLCBwYX J0aWN1bGFy bHkgaW4gZW 1lcmdpbmcg ZWNvbm9taW VzLCBhbmQg ZGl2ZXJzaW Z5aW5nIGl0 cyBwcm9kdW N0IHBvcnRm b2xpby4gVG hlIGNvbXBh bnkgYWxzby BzZWVrcyB0 byBlc3RhYm xpc2ggcGFy dG5lcnNoaX BzIHdpdGgg bG9jYWwgY2 9tcGFuaWVz IHRvIHN0cm VuZ3RoZW4g aXRzIHByZX NlbmNlIGlu IGRpZmZlcm VudCByZWdp b25zLjxicj 42LiBDb3Jw b3JhdGUgU2 9jaWFsIFJl c3BvbnNpYm lsaXR5IChD U1IpOiBBc3 RlbGxhcyBQ aGFybWEgaX MgY29tbWl0 dGVkIHRvIG dpdmluZyBi YWNrIHRvIH NvY2lldHkg YW5kIGZvc3 RlcmluZyBz dXN0YWluYW JsZSBncm93 dGggaW4gdG hlIGNvbW11 bml0aWVzIG l0IHNlcnZl cy4gVGhlIG NvbXBhbnkn cyBDU1IgcH JvZ3JhbXMg Zm9jdXMgb2 4gc3VwcG9y dGluZyBoZW FsdGhjYXJl IGluaXRpYX RpdmVzLCBw cm9tb3Rpbm cgZW52aXJv bm1lbnRhbC BzdXN0YWlu YWJpbGl0eS wgYW5kIGlu dmVzdGluZy BpbiBsb2Nh bCBjb21tdW 5pdGllcy48 YnI+SW4gc3 VtbWFyeSwg QXN0ZWxsYX MgUGhhcm1h J3MgYnVzaW 5lc3MgbW9k ZWwgcmV2b2 x2ZXMgYXJv dW5kIGludm VzdGluZyBp biBSJkQsIH N0cmF0ZWdp YyBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zLCBhIG dsb2JhbCBt YW51ZmFjdH VyaW5nIGFu ZCBzdXBwbH kgY2hhaW4s IG1hcmtldG luZyBhbmQg c2FsZXMsIG dsb2JhbCBn cm93dGggYW 5kIGV4cGFu c2lvbiwgYW 5kIGNvcnBv cmF0ZSBzb2 NpYWwgcmVz cG9uc2liaW xpdHkuIEJ5 IGZvbGxvd2 luZyB0aGlz IG1vZGVsLC B0aGUgY29t cGFueSBhaW 1zIHRvIG9m ZmVyIGlubm 92YXRpdmUg YW5kIGhpZ2 gtcXVhbGl0 eSBtZWRpY2 luZXMgdG8g aW1wcm92ZS BwYXRpZW50 IG91dGNvbW VzIGFuZCBj cmVhdGUgbG 9uZy10ZXJt IHZhbHVlIG ZvciBpdHMg c3Rha2Vob2 xkZXJzLg==

AI does have the potential to pose threats to Astellas Pharma’s products, services, or competitive positioning through various mechanisms.
Substitution: AI-driven technologies could enable the development of new treatments that may replace traditional pharmaceutical offerings. For instance, AI can facilitate faster drug discovery and development processes, potentially leading to new therapies that challenge existing products from Astellas. If competitors leverage AI more effectively in their R&D processes, they could bring innovative drugs to market more quickly, putting pressure on Astellas’s pipeline.
Disintermediation: AI may also lead to disintermediation in the pharmaceutical supply chain. Advances in telemedicine and AI-driven diagnostics can empower patients to self-manage conditions, reducing the reliance on traditional healthcare providers and, by extension, pharmaceutical companies. If patients are able to access alternatives to Astellas’s products through AI-driven health solutions or alternative therapies, Astellas may face challenges in maintaining market share.
Margin Pressure: The integration of AI in drug development and production processes has the potential to reduce costs, which may lead to increased competition and margin pressure for Astellas. As competitors use AI to streamline operations and lower their costs, they may offer products at lower prices, affecting Astellas’s profitability. Furthermore, if AI leads to the emergence of generic or biosimilar products, Astellas could see its profit margins squeezed as these alternatives become more prevalent in the market.
In summary, while AI presents significant opportunities for enhancing drug development and patient outcomes, it also poses potential threats to Astellas Pharma’s competitive positioning and financial performance through substitution, disintermediation, and margin pressure. The company will need to continuously innovate and adapt in response to these challenges to maintain its market position.

Astellas Pharma’s earnings, cash flow, and valuation can be influenced by changes in interest rates in several ways.
1. Earnings Sensitivity: Interest rates can affect Astellas’s cost of debt. If interest rates rise, the cost of servicing existing debt can increase, potentially reducing net income. Conversely, lower interest rates may reduce borrowing costs and improve profitability. Additionally, changes in interest rates can impact overall economic conditions, influencing demand for pharmaceuticals and, consequently, earnings.
2. Cash Flow Sensitivity: Cash flows are particularly sensitive to interest rates when a company has significant debt obligations. Higher interest rates would increase interest expenses, thereby reducing free cash flow available for operational investments, dividend payments, or stock buybacks. Lower rates tend to enhance cash flow by reducing interest burdens, allowing more liquidity for operational flexibility.
3. Valuation Sensitivity: Valuation is often assessed using discounted cash flow (DCF) models, where future cash flows are discounted back to their present value using a discount rate that reflects risk and opportunity costs. As interest rates rise, the discount rate usually increases, leading to a decrease in the present value of projected cash flows, thereby reducing the overall valuation of the company. Conversely, lower interest rates typically increase valuations by decreasing the discount rate used in these models.
Overall, while the direct impact of interest rates on Astellas Pharma can vary based on its capital structure, operational efficiency, and market conditions, increases in interest rates generally pose challenges, whereas decreases can provide opportunities for improved earnings, cash flow, and valuation.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvS1 dxd2ZzYzh1 dVgyZmh6NX h2TUIud2Vi cCIgYWx0PS JBc3RlbGxh cyBQaGFybW EiIHRpdGxl PSJBc3RlbG xhcyBQaGFy bWEiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgQXN0 ZWxsYXMgUG hhcm1hPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg4p yN77iPIFNp Z24gdXAgdG 8gZ2V0IDxp PiJUaGUgQ2 hlY2tsaXN0 IFZhbHVlIE ludmVzdG9y IOKAlCBBIF NtYXJ0ZXIg V2F5IHRvIF BpY2sgU3Rv Y2tzIjwvaT 4gZm9yIGZy ZWUKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdRWE4wWl cgeHNZWE1n VUdoaCBjbT FoSUhkaGN5 IEJtYjNKdF pXUWcgYVc0 Z01qQXdOUy BCMGFISnZk V2RvIElIUm 9aU0J0Wlgg Sm5aWElnYj JZZyBkSGR2 SUVwaGNHIE Z1WlhObElI Qm8gWVhKdF lXTmxkWCBS cFkyRnNJR0 52IGJYQmhi bWxsY3kgd2 dXV0Z0WVc1 diBkV05vYV NCUWFHIEZ5 YldGalpYVj AgYVdOaGJD QkRieSA0Z1 lXNWtJRVox IGFtbHpZWG RoSUYgQm9Z WEp0WVdObC BkWFJwWTJG c0lFIE52TG p4aWNqNHkg TGlCVWFHVW dZMiA5dGNH RnVlZUtBIG 1YTWdaMnh2 WW0gRnNJR2 hsWVdSeCBk V0Z5ZEdWeW N5IEJwY3lC c2IyTmggZE dWa0lHbHVJ RiBSdmEzbH ZMQ0JLIFlY QmhiaXdnWW 4gVjBJR2ww SUdGcyBjMj hnYUdGeklH IEVnYzJsbm JtbG0gYVdO aGJuUWdjSC BKbGMyVnVZ MlVnIGFXNG diM1JvWlgg SWdZMjkxYm 5SeSBhV1Z6 SUhOMVkyIG dnWVhNZ2RH aGwgSUZWdW FYUmxaQyBC VGRHRjBaWE 1zIElFVjFj bTl3WlMgd2 dZVzVrSUVG eiBhV0V1UE dKeVBqIE11 SUVGemRHVn MgYkdGeklI TndaVyBOcF lXeHBlbVZ6 IElHbHVJR1 JsZG0gVnNi M0JwYm1jZy BZVzVrSUcx aGJuIFZtWV dOMGRYSnAg Ym1jZ2JXVm thVyBOcGJt VnpJR2x1IE lITmxkbVZ5 WVcgd2dkR2 hsY21GdyBa WFYwYVdNZ1 lYIEpsWVhN c0lHbHUgWT J4MVpHbHVa eSBCMWNtOX NiMmQ1IExD QnZibU52Yk cgOW5lU3dn YVcxdCBkVz V2Ykc5bmVT IHdnWVc1a0 lHbHUgWm1W amRHbHZkWC BNZ1pHbHpa V0Z6IFpYTX VQR0p5UGog UXVJRlJvWl NCdSBZVzFs SUVGemRHIF ZzYkdGeklH bHogSUdSbG NtbDJaVyBR Z1puSnZiU0 IwIGFHVWdS M0psWlcgc2 dkMjl5WkhN ZyBZWE4wWl hJc0lHIDFs WVc1cGJtY2 cgYzNSaGNp d2dZVyA1a0 lHeHZaMjl6 IExDQnRaV0 Z1YVcgNW5J SGR2Y21RZy BiM0lnYldW emMyIEZuWl N3Z2NtVncg Y21WelpXNT BhVyA1bklI Um9aU0JqIG IyMXdZVzU1 NG8gQ1pjeU JqYjIxdCBh WFJ0Wlc1ME lIIFJ2SUhO b2FXNXAgYm 1jZ1lTQnNh VyBkb2RDQn ZiaUJ1IFpY Y2dhV1JsWV ggTWdZVzVr SUdKeSBhVz VuYVc1bklI IFJvWlcwZ2 RHOGcgYkds bVpTNDhZbi BJK05TNGdT VzRnIFlXUm thWFJwYjIg NGdkRzhnY0 doaCBjbTFo WTJWMWRHIG xqWVd4ekxD QkIgYzNSbG JHeGhjeSBC aGJITnZJR2 hoIGN5QmhJ SE4wY20gOX VaeUJtYjJO MSBjeUJ2Ym lCeVpXIGRs Ym1WeVlYUn AgZG1VZ2JX VmthVyBOcG JtVWdZVzVr IElHbHpJR0 ZqZEcgbDJa V3g1SUdsdS BkbVZ6ZEds dVp5IEJwYm lCemRHVnQg SUdObGJHd2 djbSBWelpX RnlZMmdnIF lXNWtJSFJs WTIgaHViMn h2WjNrdSBQ R0p5UGpZdU lFIEZ6ZEdW c2JHRnogSU doaGN5Qmla VyBWdUlISm xZMjluIGJt bDZaV1FnWm 0gOXlJR2ww Y3lCeiBkWE 4wWVdsdVlX IEpwYkdsMG VTQmwgWm1a dmNuUnpMQy BCcGJtTnNk V1JwIGJtY2 dZbVZwYm0g Y2dibUZ0Wl dRZyBiMjVs SUc5bUlIIF JvWlNCWGIz SnMgWk9LQW 1YTWdUVyA5 emRDQkZkR2 hwIFkyRnNJ RU52YlggQm hibWxsY3lC aSBlU0IwYU dVZ1JYIFJv YVhOd2FHVn kgWlNCSmJu TjBhWCBSMW RHVWdabTl5 IElITmxkbV Z5WVcgd2dZ Mjl1YzJWai BkWFJwZG1V Z2VXIFZoY2 5NdVBHSnkg UGpjdUlGUm 9aUyBCamIy MXdZVzU1IE lHbHpJR052 YlcgMXBkSF JsWkNCMCBi eUJuYVhacG JtIGNnWW1G amF5QjAgYn lCMGFHVWdZ MiA5dGJYVn VhWFJwIFpY TWdhWFFnYz IgVnlkbVZ6 SUhSbyBjbT kxWjJnZ2Rt IEZ5YVc5MW N5QmogYjNK d2IzSmhkRy BVZ2MyOWph V0ZzIElISm xjM0J2Ym4g TnBZbWxzYV hSNSBJSEJ5 YjJkeVlXID F6TENCcGJt TnMgZFdScG JtY2djMyBW d2NHOXlkR2 x1IFp5Qm9a V0ZzZEcgaG pZWEpsSUdG aiBZMlZ6Y3 lCaGJtIFFn WldSMVkyRj AgYVc5dUlH bHVhWCBScF lYUnBkbVZ6 IExqeGljaj Q0TGkgQkpi aUF5TURBNC BMQ0JCYzNS bGJHIHhoY3 lCaVpXTmgg YldVZ2RHaG xJRyBacGNu TjBJSEJvIF lYSnRZV05s ZFggUnBZMk ZzSUdOdiBi WEJoYm5rZ2 RHIDhnY0dG eWRHNWwgY2 lCM2FYUm9J SCBSb1pTQk piblJsIGNt NWhkR2x2Ym 0gRnNJRk53 WVdObCBJRk 4wWVhScGIy IDRnS0VsVF V5a2cgVG1G MGFXOXVZVy B3Z1RHRmli M0poIGRHOX llU3dnWTIg OXVaSFZqZE dsdSBaeUJ5 WlhObFlYIE pqYUNCdmJp QmggYm5ScE xXTmhibSBO bGNpQmtjbl ZuIGN5QnBi aUJ0YVcgTn liMmR5WVha cCBkSGt1UE dKeVBqIGt1 SUVGemRHVn MgYkdGeklH aGhjeSBCaE lITjBjbTl1 IFp5QndhWE JsYkcgbHVa U0J2WmlCdS BaWGNnWVc1 a0lHIGx1Ym 05MllYUnAg ZG1VZ2RISm xZWCBSdFpX NTBjeXdnIG QybDBhQ0J2 ZG0gVnlJRG N3SUdOcyBh VzVwWTJGc0 lIIFJ5YVdG c2N5QmogZF hKeVpXNTBi SCBrZ2RXNW taWEozIFlY a2dkMjl5Yk cgUjNhV1Js TGp4aSBjaj R4TUM0Z1ZH IGhsSUdOdm JYQmggYm5r Z2FHRnpJSC BKbFkyVnBk bVZrIElHNT FiV1Z5YjMg VnpJR0YzWV hKayBjeUJo Ym1RZ2NtIF ZqYjJkdWFY UnAgYjI1ek lHWnZjaSBC cGRITWdjSE p2IFpIVmpk SE1zSUggSm xjMlZoY21O byBMQ0JoYm 1RZ1luIFZ6 YVc1bGMzTW cgYjNCbGNt RjBhVyA5dW N5d2dhVzVq IGJIVmthVz VuSUcgSmxh VzVuSUc1aC BiV1ZrSUc5 dVpTIEJ2Wm lCMGFHVWcg Vkc5d0lEVX dJRSBOdmJY QmhibWxsIG N5Qm1iM0ln UkcgbDJaWE p6YVhSNSBJ R0o1SUVScG RtIFZ5YzJs MGVVbHUgWX k0PQogICAg ICAgIDwvc3 Bhbj4KICAg ICAgICAKIC AgICAgICA=